Please assess the completion status of the following clinical trial:

Trial Title: A Study of INCB050465 in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a Bruton's Tyrosine Kinase (BTK) Inhibitor

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women, aged 18 years or older.~* Documented failure to achieve at least partial response (PR) with, or documented disease progression after, the most recent treatment regimen.~* Radiographically measurable lymphadenopathy or extranodal lymphoid malignancy.~* Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2.~Exclusion Criteria:~* History of central nervous system lymphoma (either primary or metastatic).~* Prior treatment with idelalisib, other selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitors, or a pan PI3K inhibitor.~* Allogeneic stem cell transplant within the last 6 months, or autologous stem cell transplant within the last 3 months before the date of first dose of study treatment.~* Active graft-versus-host disease.~* Liver disease: Participants positive for hepatitis B surface antigen or hepatitis B core antibody will be eligible if they are negative for hepatitis B virus-deoxyribonucleic acid (HBV-DNA). Participants positive for anti-hepatitis C virus (HCV) antibody will be eligible if they are negative for HCV-ribonucleic acid (RNA).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Treatment A (Exposed to Ibrutinib) (Type: EXPERIMENTAL): Participants received parsaclisib 20 mg tablets, orally, once daily (QD) for 8 weeks followed by 20 mg once weekly (QW) for up to 52 weeks.~Participants who were exposed to ibrutinib before enrollment were included in this group.
- Cohort 1: Treatment B (Exposed to Ibrutinib) (Type: EXPERIMENTAL): Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 2.5 mg QD for up to 116 weeks.~Participants who were exposed to ibrutinib before enrollment were included in this group.
- Cohort 2: Treatment A (Bruton's Tyrosine Kinase Inhibitor Naïve) (Type: EXPERIMENTAL): Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 20 mg QW for up to approximately 145 weeks.~Participants who had not received a BTK inhibitor previously were included in this group.
- Cohort 2: Treatment B (Bruton's Tyrosine Kinase Inhibitor Naïve) (Type: EXPERIMENTAL): Participants received parsaclisib 20 mg tablets, orally, QD for 8 weeks followed by 2.5 mg QD for up to approximately 136 weeks.~Participants who had not received a BTK inhibitor previously were included in this group.

Based on this trial design, predict the completion outcome and termination type (if applicable).